Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mangafodipir for the Prevention of Oxaliplatin Neurotoxicity
NCT00727922Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2008
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mangafodipir, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Maximal neuropathy severity (NCI-CTC score). Started Jun 2008; status: completed.
02
Drugs
mangafodipir
Beyond the preview
Go deeper on NCT00727922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00727922.